Showing Results for
- Academic Journals (6,358)
Search Results
- 6,358
Academic Journals
- 6,358
-
From:Psychiatric Times (Vol. 30, Issue 8) Peer-ReviewedAlzheimer disease (AD) poses a public health risk of epidemic proportions worldwide. Until recently, it was defined as a type of dementia associated with abnormally high densities of amyloid-[beta] (A[beta]) plaques and...
-
From:PLoS ONE (Vol. 9, Issue 4) Peer-ReviewedObjectives: Progressive cognitive decline is a characteristic hallmark of AD. It is important to identify prognostic markers to improve patient care and long-term planning. We aimed to identify the characteristics of...
-
From:Journal of Medical Speech - Language Pathology (Vol. 19, Issue 2) Peer-ReviewedThis study examined the narrative discourse abilities of adults with mild. Alzheimer's disease (AD) (n = 8) versus age-matched normal elderly control subjects (n = 21). A timed description of the Cookie Theft picture...
-
From:Aging Health (Vol. 7, Issue 3) Peer-ReviewedAuthor(s): Kelly M Makino 1 , Anton P Porsteinsson [[dagger]â ] 1 Keywords *⢠Alzheimer'âs disease; dementia; extended-release memantine; glutamate; N-methyl-D-aspartate Alzheimer'âs disease (AD) is a...
-
From:Pharmacogenomics (Vol. 9, Issue 7) Peer-ReviewedAuthor(s): Meenal Gupta 1 , Harpreet Kaur 1 , Sandeep Grover 1 , Ritushree Kukreti [[dagger]] 1 Keywords: Alzheimer's disease; dementia; donepezil; drug response; galantamine; genes; memantine; pharmacogenomics;...
-
From:Expert Review of Neurotherapeutics (Vol. 8, Issue 1) Peer-ReviewedAuthor(s): George Razay [[dagger]] 1 , Gordon K Wilcock 2 Keywords: Alzheimer's disease; cholinesterase inhibitor; dementia; galantamine Alzheimer's disease (AD) is a chronic, progressive neurodegenerative...
-
From:Expert Review of Neurotherapeutics (Vol. 8, Issue 2) Peer-ReviewedAuthor(s): Philippe Taupin 1 Keywords: drugs; hippocampus; neural stem cell; neurological disease; neurological disorder Most nerve cells in the adult mammalian CNS are postmitotic and differentiated cells....
-
From:Expert Review of Molecular Diagnostics (Vol. 4, Issue 1) Peer-ReviewedAlzheimer's disease is the most common form of dementia in the elderly and its prevalence is rapidly rising. Although there is no cure for Alzheimer's disease, treatment can be administered to slow progression or delay...
-
From:Neural Regeneration Research (Vol. 15, Issue 3) Peer-ReviewedByline: Jakub. Hort, Martin. Valis, Francesco. Angelucci Alzheimer’s disease (AD) is a neurodegenerative disease with long preclinical phase, typically followed by a slow decline in memory, thinking and...
-
From:International Journal of Alzheimer's DiseasePeer-ReviewedHuman clinical trials seek to ameliorate the disease states and symptomatic progression of illnesses that, as of yet, are largely untreatable according to clinical standards. Ideally, clinical trials test...
-
From:Alzheimer's Research & Therapy (Vol. 12, Issue 1) Peer-ReviewedBackground Alzheimer's disease (AD) is a progressive neurodegenerative disorder of middle-aged to old individuals. The pathophysiological process of AD is believed to begin many years before the emergence of clinical...
-
From:PLoS ONE (Vol. 7, Issue 2) Peer-ReviewedWe have previously synthesized a series of hybrid compounds by linking ferulic acid to tacrine as multifunctional agents based on the hypotheses that Alzheimer's disease (AD) generates cholinergic deficiency and...
-
From:Alzheimer's Research & Therapy (Vol. 4, Issue 6) Peer-ReviewedIntroduction A substantial number of therapeutic drugs for Alzheimer's disease (AD) have failed in late-stage trials, highlighting the translational disconnect with pathology-based animal models. Methods To...
-
From:Alzheimer's Research & Therapy (Vol. 9, Issue 1) Peer-ReviewedBackground CAD-31 is an Alzheimer's disease (AD) drug candidate that was selected on the basis of its ability to stimulate the replication of human embryonic stem cell-derived neural precursor cells as well as in...
-
From:PLoS ONE (Vol. 9, Issue 12) Peer-ReviewedObjectives In this study, we developed a model of presymptomatic treatment of Alzheimer disease (AD) after a screening diagnostic evaluation and explored the circumstances required for an AD prevention treatment to...
-
From:International Journal of Alzheimer's DiseasePeer-ReviewedIt is often surprisingly difficult to tell whether a treatment for Alzheimer's disease is effective. Biomarkers might offer the potential of a quantifiable objective measure of treatment effectiveness. This paper...
-
From:Journal of Psychiatry and Neuroscience (Vol. 38, Issue 4) Peer-ReviewedBackground: Alzheimer disease is a neurodegenerative disorder that progresses with marked interindividual clinical variability. We postulate the existence of endogenous molecules within the human brain exerting an...
-
From:Contemporary Long Term Care (Vol. 25, Issue 9)Roche has acquired an exclusive worldwide license from Memory Pharmaceuticals to develop compounds for the treatment of Alzheimer's disease. Roche and Memory also will develop compounds within the same drug class for...
-
From:Nature (Vol. 475, Issue 7355) Peer-ReviewedUsing the formidable powers of the immune system to attack one of the body's own proteins seems like a risky approach. But this is what nearly all vaccines, or immunotherapies, against Alzheimer's disease aim to do....
-
From:Alzheimer's Research & Therapy (Vol. 13, Issue 1) Peer-ReviewedBackground Recent DNA/RNA sequencing and other multi-omics technologies have advanced the understanding of the biology and pathophysiology of AD, yet there is still a lack of disease-modifying treatments for AD. A...